Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet

In REACH real-world analysis, a 23% risk reduction in A1C-adjusted three-point MACE was observed for Ozempic® (semaglutide) injection compared to dulaglutide

Novo Nordisk to present array of new portfolio data including studies with semaglutide and CagriSema, expanding evidence in obesity and diabetes care at ADA 2025